Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Blood Advances|February 23, 2019
Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphomaChantana Polprasert, Yasuhide Takeuchi, Nobuyuki Kakiuchi, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
American Journal of Hematology|August 11, 2025
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR AnalysisJordan Gauthier, Kwang W Ahn, Jinalben Patel, et al.
American Journal of Hematology|August 14, 2021
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromesEmma St Martin, Alejandro Ferrer, Abhishek A Mangaonkar, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
Hematological Oncology|March 24, 2017
Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from ThailandTanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn, et al.
Leukemia|May 15, 2024
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysisTrent P Wang, Kwang W Ahn, Mazyar Shadman, et al.
Transplantation and Cellular Therapy|June 27, 2026
Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR AnalysisKitsada Wudhikarn, Lohith Gowda, Qiran Ye, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Pageof 8